What is the correct dosing and infusion rate for phenytoin (100 mg per 2 mL) in a 75‑kg adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Phenytoin Dosing for a 75-kg Adult

For a 75-kg adult, administer a loading dose of 1,125–1,500 mg of phenytoin (15–20 mg/kg) intravenously at a rate not exceeding 50 mg per minute, which will require approximately 22–30 minutes for the full infusion. 1

Dose Calculation

  • Loading dose: 15–20 mg/kg IV
  • For 75 kg patient: 1,125 mg (15 mg/kg) to 1,500 mg (20 mg/kg)
  • Using 100 mg/2 mL formulation: This equals 22.5–30 mL total volume

Infusion Rate

The maximum infusion rate is 50 mg per minute in adults 1. This is the critical safety parameter to prevent cardiovascular complications.

  • At 50 mg/min, a 1,125 mg dose takes ~22 minutes
  • At 50 mg/min, a 1,500 mg dose takes ~30 minutes

Administration Method

You have two options 1:

Option 1: Direct IV Push (Preferred for Status Epilepticus)

  • Inject slowly through a large-gauge catheter into a large peripheral or central vein
  • Do not exceed 50 mg/min
  • Flush with normal saline before and after administration
  • Never use glucose-containing solutions (causes precipitation) 2

Option 2: IV Infusion

  • Dilute in normal saline to a final concentration ≥5 mg/mL
  • Use an in-line filter (0.22–0.55 microns)
  • Complete infusion within 1–4 hours of preparation
  • Infuse at ≤50 mg/min

Critical Monitoring Requirements

Continuous monitoring during and after infusion is mandatory 1:

  • Continuous ECG monitoring
  • Blood pressure every 5–15 minutes
  • Respiratory function assessment
  • Watch for heart rate decrease >10 beats/min (slow or stop infusion) 2

Important Safety Considerations

Cardiovascular Risks

Phenytoin causes hypotension and arrhythmias, especially with rapid infusion 2, 1. If the patient is >50 years old or has atherosclerotic cardiovascular disease, reduce the infusion rate to 25 mg/min 3.

Local Toxicity

  • Verify IV patency before administration
  • Phenytoin causes severe tissue necrosis with extravasation
  • Flush line with normal saline before and after
  • Never give IM for acute seizures (erratic absorption, takes up to 24 hours to reach peak levels) 1

Dilution Requirements

  • Must dilute in normal saline only
  • Minimum concentration: 5 mg/mL
  • Incompatible with dextrose solutions (causes precipitation) 2

Expected Serum Levels

  • Target therapeutic range: 10–20 mcg/mL (total) or 1–2 mcg/mL (free) 1
  • Check level after loading dose to guide maintenance dosing
  • A 15 mg/kg dose typically achieves therapeutic levels in most patients 4

Maintenance Dosing

Following the loading dose, initiate maintenance therapy 1:

  • 100 mg IV or PO every 6–8 hours
  • Adjust based on serum levels and clinical response

Clinical Context

While phenytoin has been standard therapy for decades, fosphenytoin is preferred when available due to lower risk of cardiovascular adverse effects 2. The pediatric guidelines explicitly state this preference, and the same principle applies to adults. Additionally, emerging evidence suggests levetiracetam may be equally effective with a superior safety profile 5, though phenytoin remains guideline-recommended for status epilepticus 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.